Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fluticasone/salmeterol · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | budesonide/formoterol |
| 2 | ACTIVE_COMPARATOR | fluticasone/salmeterol |
| 3 | ACTIVE_COMPARATOR | albuterol |
| Name | Type | Description |
|---|---|---|
| budesonide | DRUG | - |
| fluticasone | DRUG | - |
| budesonide/formoterol (Symbicort) | DRUG | - |
| fluticasone/salmeterol (Advair) | DRUG | - |
| fluticasone/salmeterol (Advair Diskus) | DRUG | - |
| albuterol (Ventolin) | DRUG | - |
| budesonide/formoterol | DRUG | - |
| fluticasone/salmeterol | DRUG | - |
| albuterol | DRUG | - |
Inclusion Criteria: * Provision of signed written informed consent by patient's legal representative; when possible a signed written informed consent should be obtained from the patient themselves * Patients diagnosed as having bronchial asthma regardless of type of asthma i.e. perennial or seasona...
Fluticasone/salmeterol is used for the treatment of asthma. It is a combination therapy being developed by AstraZeneca PLC (AZN) and is currently in Phase 3 clinical development. The drug is a small molecule administered as an inhaled treatment for respiratory conditions.
Fluticasone/salmeterol is developed by AstraZeneca PLC, a multinational pharmaceutical company traded under the ticker AZN. The drug is being investigated for the treatment of asthma and is currently in Phase 3 clinical trials.
Fluticasone/salmeterol is in Phase 3 clinical development. It is an investigational drug for asthma and has not been approved by regulatory authorities. All four clinical trials for this drug have been completed, with no active trials currently ongoing.
Fluticasone/salmeterol has been studied in four completed Phase 3 clinical trials: NCT00504062, NCT00646009, NCT00646594, and NCT00646620. These trials enrolled a total of 1,536 participants with asthma, including studies in Japanese children and assessments of onset of action.
Fluticasone/salmeterol is associated with the brand name Symbicort in clinical trial records. Trials NCT00646009, NCT00646594, and NCT00646620 reference Symbicort in their titles, indicating that fluticasone/salmeterol is the active ingredient in this product.